Development of biomarkers in multiple sclerosis

Area of Science:

• Neuroimmunology
• Clinical Neurology

Background:

• Multiple sclerosis (MS) involves complex, heterogeneous pathophysiological processes like inflammation, demyelination, and axonal damage.
• These processes vary among patients, influencing disease phenotype, prognosis, and treatment response.
• Current MS therapies are expanding, yet predicting individual patient response remains a challenge.

Purpose of the Study:

• To review the concepts of biomarkers and their application in multiple sclerosis (MS) research.
• To highlight the potential of biomarkers in identifying dominant pathophysiological processes in individual MS patients.
• To discuss the role of biomarkers in tailoring therapeutic strategies and accelerating drug development for MS.

Main Methods:

• This review synthesizes existing literature on biomarkers in multiple sclerosis.
• It discusses the conceptual framework of biomarkers as surrogate endpoints.
• Concepts are tailored to specific applications within MS research.

Main Results:

• Biomarkers are essential for understanding MS heterogeneity and guiding personalized treatment approaches.
• Biomarkers can identify patient subgroups with predominant pathophysiological processes.
• They facilitate the development of combination therapies targeting multiple disease mechanisms.

Conclusions:

• Biomarkers are critical for advancing personalized medicine in multiple sclerosis.
• Their use can improve patient selection for targeted therapies and clinical trials.
• Biomarkers will be instrumental in developing novel, process-specific treatments for MS.